Lung cancer affecting the majority of patients is usually present with
advanced stage and contributes in killing more people than any other malignancy in the
world. The discovery of a number of lung cancer-molecular alterations contributes to
uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such
as erlotinib, gefitinib and crizotinib.
Pemetrexed has statistically shown significantly reduced adverse-side effects of drug
compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib
resistance in patients with non-small cell lung cancer. Thymosin α1, an
immunomodulator, significantly improves patient’s quality of life by enhancing T-cell
function, stimulation of T-cell maturation and differentiation. Various novel
compounds and chemotherapeutics were introduced in 2013 patents such as taxane,
quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenza-mide,
cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarba-mate, and
histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine,
picoplatin, and arsenic trioxide in treating small-cell lung cancer. Currently, new drugs
such as alectinib, AP26113, crizotinib, etc. are in the pipeline.
Keywords: ALK, BRACA1, cancer, carboplatin, chemotherapy, compounds,
docetaxel, drugs, EGFR-TKI, ERCC1, erotinib, FANCD2, KRAS, lung,
pemetrexed, platinum-based, RAD51, related patents, SMO, VEGF.
